Makers Laboratories Limited has scheduled a Board of Directors meeting for February 10, 2026, to consider and approve its third quarter financial results for the financial year 2025-26. The company has formally notified BSE Limited about this important corporate development through an official communication dated January 21, 2026.

Board Meeting Details

The meeting agenda focuses on reviewing and approving crucial financial documents for the company's performance assessment. The board will examine comprehensive financial data covering both quarterly and nine-month periods.

Regulatory Compliance and Trading Window

In adherence to SEBI regulations, Makers Laboratories Limited has implemented necessary trading restrictions to ensure compliance with insider trading norms. The company previously communicated these restrictions through an official letter dated December 22, 2025.

Regulatory Framework

The board meeting announcement follows strict compliance with Securities and Exchange Board of India guidelines. The company has fulfilled its disclosure obligations under multiple regulatory provisions to ensure transparency in corporate communications.

The notification was submitted pursuant to Regulation 29 read with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework mandates timely disclosure of board meetings that consider financial results to maintain market transparency and investor awareness.

Corporate Communication Process

The official communication was digitally signed and submitted through online filing systems to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai. This digital submission process ensures secure and timely delivery of critical corporate information to the stock exchange and subsequently to market participants and investors.

Makers Laboratories Limited, a pharmaceutical and chemical manufacturing company, has reported mixed financial results for the second quarter of fiscal year 2026. The company's standalone performance showed a net loss despite revenue growth, while its consolidated results demonstrated a profit.

Standalone Performance

For the quarter ended September 30, 2025, Makers Laboratories reported:

The company's standalone revenue from operations increased by 34.7% year-over-year to ₹1,372.68 crore. However, despite this growth, Makers Laboratories reported a net loss of ₹6.18 crore for the quarter, compared to a profit of ₹5.85 crore in the same period last year.

Half-Year Standalone Results

For the half-year period ended September 30, 2025:

The company's half-year revenue showed a 10.8% increase, but it reported a significant net loss of ₹70.86 crore compared to a profit in the previous year.

Consolidated Performance

On a consolidated basis, which includes the performance of its subsidiary, Resonance Specialties Limited, the company reported:

The consolidated results show a 16.8% increase in revenue from operations, but a 41.9% decrease in net profit compared to the same quarter last year.

Segment Performance

Makers Laboratories operates in two segments:

1. Pharmaceutical
2. Chemical Manufacturing

The chemical manufacturing segment remained profitable, while the pharmaceutical segment reported a loss for the quarter.

Balance Sheet Highlights

As of September 30, 2025, the company's consolidated balance sheet showed:

• Total Assets: ₹14,794.82 crore
• Total Equity: ₹7,050.59 crore
• Non-controlling Interest: ₹4,468.60 crore

Conclusion

Makers Laboratories Limited's Q2 FY26 results present a mixed picture. While the company has achieved revenue growth both on a standalone and consolidated basis, profitability remains a concern, especially in its standalone operations. The chemical manufacturing segment continues to contribute positively to the consolidated results, offsetting some of the challenges faced in the pharmaceutical segment.